12th Oct 2015 06:39
LONDON (Alliance News) - Indivior PLC said Monday that the District Court for Delaware has granted its amendment of its complaint to specifically refer to Teva Pharmaceuticals Industries Ltd's abbreviated new drug application for a generic equivalent to its opiate addiction product Suboxone.
The company's complaint now specifically refers to the application to market a generic version of two of the strengths of the Suboxone product in the US.
Indivior said that since August 2013 six companies have filed applications seeking approval to market generic equivalents for Suboxone, including Sandoz Inc last Monday.
"We remain steadfast in our belief in the strength and enforceability of our intellectual property for SUBOXONE Film," said Chief Legal Officer Javier Rodriguez in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Indivior